|Title||Improving the efficiency in new drug development based on nano-bio convergence technology|
- New bio electronic sensor based on protein is developed for new drug screening.
- New research outcome that would replace the existing cell-based new drug screening analysis method.
A joint research team composed of KRIBB (President Kyu Tae, Chang, hereinafter referred to as KRIBB) and Seoul National University (professor Jeong Sik, Chang and Tae Hyun, Park) successfully developed conducive nanotube based new bio electronic sensor that combines protein (dopamine receptor) and the research outcome was published in on the online version of ACS Nno, IF: 13.334, which is the world’s renowned journal in the nano science area under the title of Dopamine Receptor D1 Agonism and Antagonism Using a Field-Effect Transistor Assay on June 7 (Wed.)
There are many ways for new drug screening but current methods are all based on cell. The cell-based screening has limitation in terms of time and economic efficiency. Various screening methods are being developed to overcome the limitation.
The research explored new methods through nano bio convergence technology. New bio electronic sensor that would existing cell-based new drug screening analysis methods was developed utilizing protein (dopamine receptor) mass production and high purity separation and refining technology as well as nano-hybrid manufacturing original technology.
The original technology can be applied to various fields including hazardous material detection such as drug and recognition of indicator materials that can be found in cancer or a certain diseases. In terms of commercialization and practicality, the new method is regarded as an improvement a step ahead from existing technology in terms of stability and reproducibility.
Dr. Oh Seok, Kwon of Hazards Monitoring BNT Research Center of KRIBB said “one of the hot issues in domestic R&D sector is new drug development research. So many researches are being conducted but few research has been done on how to reduce time and cost involved in new drug development.” However, he added that “if the nano hybrid transistor-based bio sensor manufacturing original technology that combined highly purified receptor becomes commercial, the technology may replace the existing screening method. It will lead to time and cost reduction and serve as an opportunity for Korea to improve international competitiveness in the new drug development industry.